Enhancer of zeste homologue 2 (EZH2), a histone methyltransferase, has been reported to be highly expressed in many human tumors, including BC, and its higher expression has a direct positive correlation with malignant invasion and EMT phenotypes and poor prognosis [18, 19]. Here, EZH2 is linked to breast cancer.